Crohn'sCanada   

Addressing the alarming rise of the bacterium "Mycobacterium avium Paratuberculosis" in the environment and the growing evidence linking this bacterium to Crohn's disease.

 

Founders: Diane and Michael Fagen

Contact Info: dianef84@yahoo.com

Home

Our Mission and our Goals

History of Crohn's Disease, Johne's disease, Mycobacterium avium Paratubercuosis

Recent Article Updates

Links to Articles
Page 2....3....4.....5

Perception of Risk

The Precautionary Principle

What is a Reportable Disease

Health of Animals Act, SC 1990, c 21

List of Reportable Diseases and REGULATIONS PRESCRIBING CERTAIN DISEASES AS REPORTABLE DISEASES

NRC National Science Library

Public Health Agency of Canada

Never In My Milk

Links

Messageboard

ree Republic/News Activism/Topics - Post Article

Research

La Presse,  April 8, 2001,  Never in My Milk? by Marie France Coutu

The Canadian Media


Canadian Medical and Government

Canadian Veterinary

Canadian Raw Milk Advocacy Group

 

Let's Talk



 

Taking Action

Link To Us

Does Mycobacterium Paratuberculosis cause Crohn's disease by Alan Kennedy  

(PARA) PARATUBERCULOSIS AWARENESS & RESEARCH ASS.,INC



Shafran's Gasterology Center

The Johne's Information Center

History of Early Research on Crohn's disease

Dr. B. Crohn

Got Milk? by Michael Greger, MD Updated January 2001

THE CROHN'S CONNECTION  by Lisa Chamberlain

Dire Warnings About Johne’s
Disease A wake-up call for the dairy industry?

Micobacteria and Crohn's Disease

Dr. Chiodini's Tables

American and European Links

University of Wisconsin School of Veterinary Medicine

Health Canada

Action Medical Research

 

University of Guelph

NACC

 

 
Founded: September 2001, updated December 27, 2011
   
   
 
 
 

 

MSWorld Forums: Tara's Nutrition and Supplement Notebook/Page 8/ Question: Anyone Taking Alpha Lipoic Acid. The answer to this thread is from members of MSWorld, talks alot about Alpha Lipoic Acid in combination with Acetyl L Carnitine.

 

ALC Can Help in Multiple Sclerosis:/Acetyl L-Carnitine May Help with Chronic Fatigue Mental fatigue, in particular, is improved by this energy-metabolism nutrient By Dr. Edward R. Rosick

In a randomized, double-blind, crossover trial in Italy that compared the efficacy of ALC with that of amantadine (a commonly used prescription drug to treat MS fatigue), 36 patients (67% female, average age 44) were treated for 3 months with either amantadine (100 mg twice daily) or ALC (1 g twice daily). The patients then stopped taking ALC or amantadine for 3 months, after which they switched to the opposite treatment for another 3 months. A significant majority (70%) of the patients taking ALC reported improvement in their levels of fatigue, versus 43% of those taking amantadine. Based on the data obtained, the researchers calculated that 29% of the ALC patients were clinically improved, versus 21% of the amantadine patients. They concluded, “The results of this study showed that ALCAR [ALC] is well tolerated by patients with MS and is more effective than amantadine in the treatment of MS-related fatigue.” Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl-L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomized, double-blind, crossover trial. J Neuro Sci 2004;218:103-8.

 

Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial Valentina Tomassini a , Carlo Pozzilli a, *, Emanuela Onesti a , Patrizio Pasqualetti b , Fabiana Marinelli a , Angela Pisani a , Cesare Fieschi a

 

Acetyl-L-Carnitine/"-Lipoic Acid Supplements OVERVIEW This material was prepared for the National Cancer Institute (NCI) for consideration by the Chemical Selection Working Group (CSWG) by Technical Resources International, Inc. under contract no. N02-07007

Multiple Sclerosis "Oxidative stress in patients with multiple sclerosis" Syburra C; Passi S, Ukr Biokhim Zh 1999 May-Jun;71(3):112-5


"High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis" Nieves J; Cosman F; Herbert J; Shen V; Lindsay R, Neurology 1994 Sep;44(9):1687-92


"High Dose Antioxidant Supplementation to MS Patients: Effects on Glutathione Peroxidase, Clinical Safety, and Absorption of Selenium" Mai, Jesper, et al, Biological Trace Element Research, 1990;24:109-117.

 

"Homocysteine and Vitamin B12 in Multiple Sclerosis" Baig, Shahid, M. and Qureshi, G. Ali, Biogenic Amines, 1995;11(6):479-485.

 

 

 

 

 

 

 

 

 

 

 

 

 
 
 

 

 

 

 

 

 

 

 

 



 

 


 


 

...

 

 

 




 













 


 


   
 

 Disclaimer:
MAP-Canada does not advocate a particular cause of Crohn's disease.  Our website is intended only to present evidence.  Our readers may draw their own conclusions.  We are not medical specialists and do not offer any treatment or nutritional advice.  Our mission is not to lay blame on any individual or industry, but rather to urge the Government of Canada to address the evidence presented on this site.

Mise au Point:
MAP-Canada ne recommande aucune théorie particulière sur la cause de la maladie de Crohn.L'intente de notre site Web est simplement de présenter certaineévidence mais vous pouvez arriver à vos propres conclusions.Nous ne pouvons donner de conseils de nature médicale ou alimentaire. Notre mission ne consiste aucunement à blâmer un individuou une industrie mais
plutôt à s'assurer que le Gouvernement du Canada aborde l'évidence que nous présenton

 

 

MAP-Canada would like to extend a very sincere thank you to Yanik Chicoine at www.mirweb.com of Montreal for his generosity and assitance in hosting and the mounting of this site.

MAP-Canada aimerait remercier sincerement Yanik Chicoine a www.mirweb.com de Montreal pour sons générosité et leur assistance pour l'hébergement et la programation du site